What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide investors and the public with a comprehensive update on Amgen Inc.'s financial performance and operational status for the second quarter of 1996, ending on June 29, 1996. It fulfills Amgen's requirement to report quarterly to the U.S. Securities and Exchange Commission (SEC).

What specific financial details can be gleaned from the provided filing information?

Unfortunately, the provided text only consists of the filing metadata and directory listing, not the actual financial statements or management discussion. Therefore, specific financial details such as revenue, net income, cash flow, or balance sheet figures cannot be determined from this information alone.

Where can I find the full content of this 10-Q filing to get detailed financial information?

The full content of this 10-Q filing, including the financial statements and accompanying notes, can be accessed through the SEC's EDGAR database. You would typically search for Amgen Inc. (AMGN) and the filing date or report period on the SEC's official website.

What does the filing date of August 11, 1996, signify?

The filing date of August 11, 1996, indicates when Amgen Inc. officially submitted its quarterly report to the SEC. This date is important as it signifies the official availability of the company's financial and operational data for the reporting period to the public and investors.

AMGN 10-Q Quarterly Report Q2 FY1996 — Revenue, Net Income, EPS

Summary

This 10-Q filing from Amgen Inc. for the period ending June 29, 1996, provides a snapshot of the company's financial performance and operations during the second quarter of 1996. As a leading biotechnology company, Amgen's results are closely watched for its innovation and product pipeline. Investors should note that the available data is limited to the filing metadata and directory listing, which indicates the presence of financial statements and other disclosures. Without the actual content of the financial statements, a detailed analysis of revenue, profitability, cash flows, and balance sheet changes is not possible. However, the filing confirms Amgen's ongoing reporting obligations and its position within the SEC's EDGAR system, suggesting continued business operations and public market participation.

Key Highlights

1Amgen Inc. (AMGN) filed its quarterly report (10-Q) for the period ending June 29, 1996, on August 11, 1996.
2The filing confirms Amgen's continued compliance with SEC reporting requirements.
3The provided data indicates the existence of various financial and operational documents within the filing.
4As a significant player in the biotechnology sector, this report would typically contain updates on product development, sales, and research initiatives.
5Investors rely on these quarterly reports for timely information on the company's financial health and strategic direction.
6The filing was made publicly available through the SEC's EDGAR system.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 1996

Summary

Key Highlights

Frequently Asked Questions